Exploring new ways to personalize treatment and prevention for ALS using environmental and genetic data.
Developing novel strategies for personalized treatment and prevention of ALS: Leveraging the global exposome, genome, epigenome, metabolome, and inflammasome with data science in a case/control cohort
This study is looking at how things like your genes, environment, and body processes work together to influence ALS, and it hopes to find new ways to treat and prevent the disease by gathering information from patients about their health and surroundings.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10870001 on NIH RePORTER |
What this research studies
This research investigates the complex interactions between environmental factors, genetics, and biological processes in the development of amyotrophic lateral sclerosis (ALS). By analyzing data from various sources, including genomics, epigenomics, and metabolomics, the study aims to identify how these factors contribute to ALS risk and progression. Patients may be asked to provide information about their environmental exposures and health history, which will be used to develop personalized treatment strategies. The goal is to uncover new therapeutic targets and prevention methods for ALS.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with ALS or those at risk due to genetic or environmental factors.
Not a fit: Patients with other unrelated neurological disorders or those not exposed to environmental risk factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for ALS patients.
How similar studies have performed: Previous research has shown promise in understanding ALS through genetic and environmental interactions, but this approach is innovative and seeks to expand on those findings.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Feldman, Eva Lucille — University of Michigan at Ann Arbor
- Study coordinator: Feldman, Eva Lucille
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.